ArticleNucleic acids research2026
MolGlueDB: an online database of molecular glues.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Delivering Degradation: Nanomedicine and Programmable Proximity Platforms for Targeted Protein Degradation.Pharmaceutics · 2026Review
- Linkerability of Protein Ligands: Insights From Cocrystal Structures and Implications for DNA-Encoded Libraries.Molecular informatics · 2026Article
- The evolution of cancer therapeutics: from "undruggable" to "drugged".Translational cancer research · 2026Article
- Mapping Scientific Landscapes and Therapeutic Innovations of Targeted Protein Degradation: A Scientometric Review.Pharmaceutics · 2026Review
- Redirecting TRIM21 with TRIMTACs for the targeted degradation of multimeric proteins.The FEBS journal · 2026Review
- Disrupting the Undruggable: Emerging Modalities for Targeting Protein-Protein Interactions in Oncology.Biology · 2026Review
- A Novel Paradigm for Targeting Challenging Targets: Advancing Technologies and Future Directions of Molecular Glue Degraders.Molecules (Basel, Switzerland) · 2026Review
- The 2026 Nucleic Acids Research database issue and the online molecular biology database collection.Nucleic acids research · 2026Article
- Clues for glues: from serendipity to nature's blueprints in degrader discovery.Essays in biochemistry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Molecular glue degraders (MGDs) and proteolysis-targeting chimeras (PROTACs) are two prominent approaches in targeted protein degradation, both leveraging the ubiquitin-proteasome system to induce selective protein degradation. While PROTACs rely on heterobifunctional motifs, MGDs possess more compact, mono-affinitive molecular structures, offering distinct advantages in drug-like properties. Over the past decade, significant progress has been made in development of MGDs, with over 20 MGDs advancing through clinical trials. Despite these advancements, the field remains in its early stages due to the novel mode of action and complex design principles. To facilitate rational design of MGDs, we present MolGlueDB, an open-access, web-based database consolidating information from 241 publications (January 2001-May 2025). MolGlueDB contains 1840 entries, including 1629 distinct MGDs, 28 recruiting proteins, and 94 targets, with comprehensive data on chemical structures, binding affinities, degradation capacities, biological activities, and physicochemical properties. The platform supports both text-based and structure-based searches, enabling users to refine results based on specific molecular attributes. MolGlueDB is freely accessible at https://www.molgluedb.com, providing a valuable resource for advancing research of MGDs and accelerating drug discovery in the field of targeted protein degradation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.